AOL Money & Finance

tdg posts

Feed

Analyst calls: ETR, THO, AMN, DF, FOSL, NSRGY . . .

Analyst upgrades:
  • Baird expects Thor Industries (NYSE: THO) to benefit from industry consolidation and the eventual recovery. Shares were upgraded to Neutral from Underperform.
  • Jefferies upgraded SPSS Inc. (NASDAQ: SPSS) to Buy from Hold on valuation and believes the company's cost cuts will be positive for EPS. The company's target was lowered to $28 from $29.
  • Banc of America upgraded shares of Entergy (NYSE: ETR) to Buy from Neutral on valuation and believes the company is unlikely to spin-off Enexus by year-end. They believe a spin-off in 2009 or no spin at all suggests a higher share price from current levels. The company's target was raised to $104 from $101.50.
  • AMN Healthcare (NYSE: AMN) was upgraded to hold from Sell at Citigroup.
  • Argus upgraded Choice Hotels (NYSE: CHH) to Hold from Sell.
  • Transdigm Group (NYSE: TDG) was lifted to Buy from Neutral at UBS.

Analyst downgrades:

Continue reading Analyst calls: ETR, THO, AMN, DF, FOSL, NSRGY . . .

Analyst initiations: WX, MYGN, CYPB and KNOL

MOST NOTEWORTHY: Aerospace stocks, WuXi Pharma, Myriad Genetics, Cypress Bioscience and Knology were today's noteworthy initiations:
  • LYON initiated shares of aerospace stocks including Goodrich Corporation (NYSE: GR), TransDigm Group Inc (NYSE: TDG) and Triumph Group Incorporated (NYSE: TGI) with Add ratings and a $74 target, $45 target and $90 target, respectively.
  • WuXi Pharmatech (NYSE: WX) was started with a Hold rating and $29 target at Jefferies on valuation. JP Morgan started shares with a Neutral rating and Credit Suisse initiated shares with an Outperform rating.
  • Myriad Genetics Inc (NASDAQ: MYGN) was started with a Hold rating and $50 target at Citigroup, as the firm is cautious on the Phase III Flurizan results and does not recommend putting new money here at these levels.
  • Citigroup also initiated shares of Cypress Biosciences Inc (NASDAQ: CYPB) with a Buy rating and $22 target as the firm believes Milnacipran has sufficient database for approval and is capable of gaining meaningful market share as firstline therapy.
  • Knology Inc (NASDAQ: KNOL) was initiated with a Buy rating and $25 target at BWS Financial, as the firm believes the company's growth potential is greater than other cable companies through a business plan that allows it to have operations in all regions of the U.S.
OTHER INITIATIONS:

Symbol Lookup
IndexesChangePrice
DJIA+73.0010,270.47
NASDAQ+18.862,167.88
S&P 500+6.241,093.48

Last updated: November 14, 2009: 10:35 AM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

WalletPop Headlines

AOL Business News

BioHealth Investor Headlines

Sponsored Links

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance